Belimumab (Benlysta) for Lupus Nephritis (online only)

Date: September 23, 2021 Issue #:  1634Summary:  The B-lymphocyte stimulator (BLyS)-specific inhibitor belimumab (Benlysta– GSK), which was approved earlier for treatment of active, autoantibody-positive, nonrenal, systemic lupus erythematosus (SLE), has now been approved for use in addition to standard therapy for treatment of active lupus nephritis in adults. Belimumab is the first drug to be approved in the US for treatment of both SLE and lupus nephritis.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Azathioprine belimumab Benlysta Cellcept corticosteroids Cyclophosphamide Cytoxan Imuran Lupkynis Lupus Mycophenolate mofetil Prograf Rituxan Rituximab Tacrolimus voclosporin Source Type: research